30 July 2025
: Case report 
Successful Management of Severe Refractory ARDS in Hemophagocytic Lymphohistiocytosis with VV-ECMO: A Case Report and Analysis
Challenging differential diagnosis, Management of emergency care, Rare disease
Mengqi Guan BCDE 1,2, Yan Qian C 3, Zihua Tang F 1,2, Yingya Cao C 1,2,4, Xiaogan Jiang ADG 1,2, Weihua Lu ACG 1,2*, Qiancheng Xu A 1,2,4DOI: 10.12659/AJCR.949154
Am J Case Rep 2025; 26:e949154
Table 3 ECMO support in various reports for hemophagocytic lymphohistiocytosis: modes, duration, and outcomes.
| Author and publication year | Population | Sample size | ECMO mode | ECMO running time | Outcomes |
|---|---|---|---|---|---|
| Wu, 2008 []6 | Children | 1 | VV-ECMO | 122 h | Survived |
| Rossetti, 2012 []7 | Children | 1 | VA-ECMO | 5 days | Survived |
| Lucchese, 2013 []8 | Children | 1 | VA-ECMO | 36 h | Deceased |
| Saites, 2016 []9 | Adult | 1 | VV-ECMO | 4 days | Survived |
| Cheng, 2016 []10 | Children | 1 | VV-ECMO | 140 h | Survived |
| Cashen, 2017 []4 | Children | 30 | 19 VA-ECMO11 VV-ECMO | > 6 days in 43.3% patients | 70% Mortality |
| Meneghel, 2020 []11 | Toddler | 1 | VA-ECMO | 6 days | Survived |
| von Bahr Greenwood, 2021 []12 | Adult | 4 | 3 VA-ECMO1 VV-ECMO | 31 [12 to 51] days | All survived |
| Weyand, 2021 []13 | Infant, toddler or children | 6 | Not reported | 1–29 days | 50% Mortality |
| Chizinga, 2021 []14 | Adult | 1 | VA-ECMO | 9 days | Survived |
| Hundal, 2022 []15 | Adult | 1 | VV-ECMO | 2 weeks | Survived |